Literature DB >> 12062678

Determination of the binding parameter constants of Renagel capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography.

Ronald A Swearingen1, Xi Chen, John S Petersen, Kristine S Riley, Donghui Wang, Eugene Zhorov.   

Abstract

Sevelamer hydrochloride is a cross-linked polymeric amine; it is the active ingredient in Renagel capsules and tablets. Sevelamer hydrochloride is indicated for the control of hyperphosphatemia in patients with end-stage renal disease. The binding parameter constants of sevelamer hydrochloride were determined using the Langmuir approximation for three different dosage forms at pH 4.0, 5.5 and 7.0. The three dosage forms were Renagel 403 mg capsules, Renagel 400 mg tablets and Renagel 800 mg tablets. The results demonstrate the equivalency of all three dosage forms at each pH. The results also demonstrate a shift in the binding mechanism from pH 4.0 to 7.0.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12062678     DOI: 10.1016/s0731-7085(02)00007-9

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

1.  Common Deficiencies of in vitro Binding Bioequivalence (BE) Studies Submitted in Abbreviated New Drug Applications (ANDAs).

Authors:  Dongmei Lu; Diana Vivian; Ping Ren; Yongsheng Yang; Hongling Zhang; Xiaojian Jiang; Ethan Stier
Journal:  AAPS J       Date:  2018-01-11       Impact factor: 4.009

2.  Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.

Authors:  Helen Vlassara; Jaime Uribarri; Weijing Cai; Susan Goodman; Renata Pyzik; James Post; Fabrizio Grosjean; Mark Woodward; Gary E Striker
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-29       Impact factor: 8.237

3.  Pre-treatment of dairy and breast milk with sevelamer hydrochloride and sevelamer carbonate to reduce phosphate.

Authors:  Renske Raaijmakers; Lambertus M W Houkes; Cornelis H Schröder; Johannes L Willems; Leo A H Monnens
Journal:  Perit Dial Int       Date:  2013-05-01       Impact factor: 1.756

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.